FYFang Ye

Fang Ye

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fang Ye has a total of 48 co-authors. Here are the top co-authors by number of shared publications:

  • Qian Wang

    Shenzhen University 3 Shenzhen, Guangdong

    2 shared publications
  • Yang Du

    Affiliation Kobilka Institute of Innovative Drug Discovery, The Second Affiliated Hospital, Shenzhen Futian Biomedical Innovation R&D Center, School of Medicine, Chinese University of Hong Kong, Shenzhen, Guangdong, China

    2 shared publications
  • Binghao Zhang

    Kobilka Institute of Innovative Drug Discovery, Shenzhen Key Laboratory of Steroid Drug Discovery and Development, School of Medicine, The Chinese University of Hong Kong, 518172 Shenzhen, Guangdong, China

    1 shared publication
  • Chao Tang

    Center for Quantitative Biology, Peking University, Beijing 100871, China; Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China

    1 shared publication
  • Chen Qiu

    Kobilka Institute of Innovative Drug Discovery, Shenzhen Key Laboratory of Steroid Drug Discovery and Development, School of Medicine, The Chinese University of Hong Kong, 518172 Shenzhen, Guangdong, China

    1 shared publication
  • Cuihan Shi

    Shenzhen Institute of Advanced Technology

    1 shared publication

Latest Publications

  • Open Access

    Development of a novel peripherally acting alpha2A-adrenergic receptor antagonist for anti-diabetic

    by Feng Hong, Jingyi Wang, Dongsheng Chen, Qian Wang, Shiyi Gan, Fang Ye, Lihua Chen, Huixia Ren, Tongran Zhang, Yinfang Xie, et al.

    Summary: Yohimbine, a potent alpha2A-adrenergic receptor (α 2A AR) antagonist, was found therapeutic potential for type 2 diabetes through improving insulin release. However, the adverse side effects mediated by its actions in the brain hampered its use. Here, based on molecular docking analysis and structural modification, we have developed a novel peripherally acting yohimbine derivative (CDS479-2). CryoEM data found that yohimbine and CDS479-2 have similar interactions with the structure of α 2A AR. Importantly, CDS479-2 shows similar α 2A AR antagonist activity as yohimbine, but with very limited access to the brain, and thus avoiding the unwanted central effects such as hypertension and anxiety. Acute administration of CDS479-2 by injection or gavage lowered blood glucose levels and improved glucose tolerance in the high-fat diet-induced obesity (DIO) mice, an animal model for human type 2 diabetes. Remarkably, DIO mice received 2 weeks of daily administration of CDS479-2, but not yohimbine, exhibited sustained normoglycaemia, and increased density of the insulin-producing beta cells, in which important proliferation genes were found upregulated. Moreover, the overall protein expression levels of their pancreas were more similar to that of the healthy chow-fed mice. Thus, CDS479-2 may indicate a new direction for type 2 diabetes treatment. Importantly, the strategy we employed in this study will inspire the optimization for drugs that with both peripheral and central targets. Graphic

  • Open Access

    Structural basis for the ligand recognition and G protein subtype selectivity of kisspeptin receptor

    by Zhangsong Wu, Geng Chen, Chen Qiu, Xiaoyi Yan, Lezhi Xu, Shirui Jiang, Jun Xu, Runyuan Han, Tingyi Shi, Yiming Liu, et al.

    Kisspeptin receptor (KISS1R), belonging to the class A peptide-GPCR family, plays a key role in the regulation of reproductive physiology after stimulation by kisspeptin and is regarded as an attractive drug target for reproductive diseases. Here, we demonstrated that KISS1R can couple to the G i/o pathway besides the well-known G q/11 pathway. We further resolved the cryo–electron microscopy (cryo-EM) structure of KISS1R-G q and KISS1R-G i complexes bound to the synthetic agonist TAK448 and structure of KISS1R-G q complex bound to the endogenous agonist KP54. The high-resolution structures provided clear insights into mechanism of KISS1R recognition by its ligand and can facilitate the design of targeted drugs with high affinity to improve treatment effects. Moreover, the structural and functional analyses indicated that conformational differences in the extracellular loops (ECLs), intracellular loops (ICLs) of the receptor, and the “wavy hook” of the Gα subunit may account for the specificity of G protein coupling for KISS1R signaling.